Clinical Trials
2 trialsNCT03367247 2026-03-10
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
Dana-Farber Cancer Institute
Phase NA Completed
NCT02417753 2017-05-15
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated